Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) Enterprise Value (2018 - 2025)

BioNexus Gene Lab's Enterprise Value history spans 8 years, with the latest figure at -$4.0 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$4.0 million for Q4 2025, up 28.89% from a year ago — trailing twelve months through Dec 2025 was -$4.0 million (up 28.89% YoY), and the annual figure for FY2025 was -$4.0 million, up 28.89%.
  • Enterprise Value for Q4 2025 was -$4.0 million at BioNexus Gene Lab, down from -$3.1 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$297084.0 in Q2 2023 to a low of -$6.1 million in Q3 2023.
  • The 5-year median for Enterprise Value is -$2.3 million (2021), against an average of -$2.8 million.
  • The sharpest move saw Enterprise Value tumbled 1233.7% in 2024, then soared 81.29% in 2025.
  • Year by year, Enterprise Value stood at -$2.1 million in 2021, then grew by 0.24% to -$2.1 million in 2022, then tumbled by 113.21% to -$4.5 million in 2023, then decreased by 25.75% to -$5.7 million in 2024, then grew by 28.89% to -$4.0 million in 2025.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$4.0 million, -$3.1 million, and -$3.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.